Your browser doesn't support javascript.
loading
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.
Robert, Caroline; Long, Georgina V; Brady, Benjamin; Dutriaux, Caroline; Di Giacomo, Anna Maria; Mortier, Laurent; Rutkowski, Piotr; Hassel, Jessica C; McNeil, Catriona M; Kalinka, Ewa Anna; Lebbé, Céleste; Charles, Julie; Hernberg, Micaela M; Savage, Kerry J; Chiarion-Sileni, Vanna; Mihalcioiu, Catalin; Mauch, Cornelia; Arance, Ana; Cognetti, Francesco; Ny, Lars; Schmidt, Henrik; Schadendorf, Dirk; Gogas, Helen; Zoco, Jesús; Re, Sandra; Ascierto, Paolo A; Atkinson, Victoria.
Afiliación
  • Robert C; Gustave Roussy, Villejuif, France.
  • Long GV; Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Brady B; Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.
  • Dutriaux C; Cabrini Health, Melbourne, Victoria, Australia.
  • Di Giacomo AM; Hôpital Saint André Centre Hospitalier Universitaire, Bordeaux, France.
  • Mortier L; Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy.
  • Rutkowski P; University of Lille, INSERM U1189, Service de Dermatologie, Chu Lille, Lille, France.
  • Hassel JC; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • McNeil CM; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Kalinka EA; Chris O'Brien Lifehouse, Melanoma Institute Australia, and Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
  • Lebbé C; Polish Mother's Memorial Hospital-Research Institute, Lodz, Poland.
  • Charles J; Université de Paris, INSERM U976, and Dermatology and CIC, AP-HP, Saint Louis Hospital, Paris, France.
  • Hernberg MM; Grenoble Alpes University Hospital, INSERM U1209, Grenoble Alpes University, Grenoble, France.
  • Savage KJ; Helsinki University Hospital, Helsinki, Finland.
  • Chiarion-Sileni V; British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada.
  • Mihalcioiu C; Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy.
  • Mauch C; Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada.
  • Arance A; University Hospital Cologne and Centrum für Integrierte Onkologie Köln, Bonn, Germany.
  • Cognetti F; Hospital Clínic Barcelona, Barcelona, Spain.
  • Ny L; Regina Elena Institute, Rome, Italy.
  • Schmidt H; Department of Oncology, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Schadendorf D; Aarhus University Hospital, Aarhus, Denmark.
  • Gogas H; Department of Dermatology, Comprehensive Cancer Center, University Hospital Essen, Essen, Germany.
  • Zoco J; German Cancer Consortium, Heidelberg, Germany.
  • Re S; National and Kapodistrian University of Athens, Athens, Greece.
  • Ascierto PA; Syneos Health, Braine l'Alleud, Belgium.
  • Atkinson V; Bristol Myers Squibb, Princeton, NJ.
J Clin Oncol ; 38(33): 3937-3946, 2020 11 20.
Article en En | MEDLINE | ID: mdl-32997575
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Nivolumab / Melanoma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: J Clin Oncol Año: 2020 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Nivolumab / Melanoma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: J Clin Oncol Año: 2020 Tipo del documento: Article País de afiliación: Francia